PDS Biotechnology Corp.

Quick facts

Phase 3 pipeline

• Pembrolizumab Monotherapy · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• PDS Biotechnology Corp. portfolio CI brief
• PDS Biotechnology Corp. pipeline updates RSS